‘QC’ process for cell development identified in Scripps Florida study

A study recently published by scientists at the Florida campus of the Scripps Research Institute outlines the assembly process of the ribsosome

Amy Swinderman
JUPITER, Fla.—A study recently published by scientists atthe Florida campus of the Scripps Research Institute outlines the assemblyprocess of the ribsosome, a large complex of RNA and protein which catalyzesprotein translation, and may ultimately present opportunities to treatconditions affected by abnormal cell growth, such as bacterial infections andeven cancer.
 
 
Ribosomes are large macromolecular machines that catalyzeprotein synthesis in all cells. While their structure and function is wellunderstood, the principles and mechanisms governing their assembly from theconstituent ribosomal RNA (rRNA) and ribosomal proteins (r-proteins) remainpoorly understood. What is known is that eukaryotes, a large macromolecularmachinery comprised of more than 200 protein and RNA factors, transientlyassociate with assembling ribosomes to facilitate the transcription ofpre-rRNA, the modification and cleavage of rRNA precursors, the folding of rRNAas well as the binding of r-proteins. While most of these proteins areessential and conserved from yeast to humans, their function remains oftenunknown.
 
 
Using a combination of approaches including biochemistry,mechanistic enzymology, protein engineering, structural methods and yeastgenetics, the laboratory of Scripps Research Associate Prof. Katrin Karbstein setout to study eukaryotic ribosome assembly at the molecular level. The lab'sultimate goal is to understand the function of assembly factors, the order ofevents and the rationale for this order.
 
 
The study led by Karbstein's lab, "A Translation-Like CycleIs a Quality Control Checkpoint for Maturing 40S Ribosome Subunits," waspublished in the July 6 edition of the Elsevier journal Cell, and shows that a "quality control" function exists forribosomal subunits that use the protein-production process called translationto do a kind of test-run, but ultimately don't produce a protein.
 
"What is important here is that the test cycle involves thesame translational factors that are involved in normal translation," saysKarbstein, a lead author of the study. "It's the most elegant and efficient wayto produce perfect ribosomes."
 
 
Ribosomes are the targets of many commercially usedantibiotics and represent a promising area of research because of theimportance of ribosome assembly and function for cell growth. But ribosomes mayhold the key to a much greater medical need—cancer—as there arewell-established links between defects in ribosome assembly and most forms ofthe disease.
 
 
Karbstein and her colleagues were able to show that duringtranslation, the newly made ribosome subunit initially joins with itscomplementary preexisting subunit to form a much larger complex through theinfluence of a single translation factor. This large ribosome complex containsno messenger RNA, which is blocked by assembly factors, and thus produces noprotein. Once the major functions of the smaller ribosome subunit have beeninspected and approved, another translation factor breaks up the complex, andactual protein production occurs. 
 
"For several of the assembly factors, it has been shown thatthe presence of a molecule is required, but if you take one out, it's like adomino effect—the whole thing falls apart," explains Karbstein.
 
 
The study noted that the majority of assembly factorsinvolved in this translation-like test cycle are conserved in creatures rangingfrom one-celled organisms to humans, suggesting that this evolutionarymechanism is common to all.
 
 
"Our work has been one of the first—and definitely thecleanest—work to describe the potential quality control step. The truth is,there is no data to suggest that if you disrupt this process, there will be alack of quality control, but the pathway we uncovered has all the hallmarks toensure a quality-control system."
 
 
Having shown that parts of this translation-like cycle areused to inspect ribosomal particles before releasing them into the translationpool, Karbstein and her colleagues are now trying to uncover more informationabout the degradation pathway, with the hope of finding a way to disable it.
 
 
"Eventually, we could try to develop small molecules tomodulate this pathway to help diseases like cancer, where too many ribosomes areimplicated, and other diseases that don't have enough ribosomes, like DiamondBlackfan Anemia," says Karbstein.
 
 
The first author of the study was is Bethany S. Strunk ofScripps Research. Other authors included Megan N. Novak, an undergraduate fromFurman University who worked at Scripps as a summer intern, and Crystal L.Young, also of Scripps Research. The study was supported by the U.S. NationalInstitutes of Health, the National Science Foundation and the Scripps ResearchKellogg School of Science and Technology.
 
 


Amy Swinderman

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue